Comparing universal Lynch syndrome tumor-screening programs to evaluate associations between implementation strategies and patient follow-through

Genetics in Medicine

Volumn 16, Issue 10, 2014, Pages 773-782

  Cragun, Deborah ^a   DeBate, Rita D ^b   Vadaparampil, Susan T ^a   Baldwin, Julie ^b   Hampel, Heather ^c   Pal, Tuya ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

hereditary colorectal cancer; Lynch syndrome; Public Health Genomics; qualitative comparative analysis; RE AIM

Indexed keywords

CLINICAL TRIAL; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; COMPARATIVE STUDY; EARLY DIAGNOSIS; FOLLOW UP; GENETIC COUNSELING; GENETIC SCREENING; GENETICS; GERMLINE MUTATION; HEALTH SURVEY; HUMAN; MULTICENTER STUDY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA;

COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; GENETIC COUNSELING; GENETIC TESTING; GERM-LINE MUTATION; HEALTH SURVEYS; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84919326756     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.31     Document Type: Article

References (39)

1. American Cancer Society. Colorectal cancer facts & figures 2011–2013. http://www.cancer.org/Research/CancerFactsFigures/ColorectalCancerFactsFigures/colorectal-cancer-facts-figures-2011-2013-page. Accessed 20 July 2013.
2. Hampel, H., Frankel, W.L., Martin, E., Feasibility of screening for Lynch syndrome among patients with colorectal cancer. 10.1200/JCO.2008.17.5950 J Clin Oncol 26 (2008), 5783–5788.
3. Stoffel, E., Mukherjee, B., Raymond, V.M., Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. 10.1053/j.gastro.2009.07.039 Gastroenterology 137 (2009), 1621–1627.
4. Barrow, E., Alduaij, W., Robinson, L., Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. 1:STN:280:DC%2BD1cnltFSktw%3D%3D 10.1111/j.1399-0004.2008.01035.x Clin Genet 74 (2008), 233–242.
5. Hampel, H., Stephens, J.A., Pukkala, E., Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. 10.1016/j.gastro.2005.05.011 Gastroenterology 129 (2005), 415–421.
6. Barrow, E., Robinson, L., Alduaij, W., Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. 1:STN:280:DC%2BD1M7jvFantA%3D%3D 10.1111/j.1399-0004.2008.01125.x Clin Genet 75 (2009), 141–149.
7. Watson, P., Vasen, H.F., Mecklin, J.P., The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. 1:CAS:528:DC%2BD1cXnsF2jt7w%3D 10.1002/ijc.23508 Int J Cancer 123 (2008), 444–449.
8. Järvinen, H.J., Aarnio, M., Mustonen, H., Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. 10.1016/S0016-5085(00)70168-5 Gastroenterology 118 (2000), 829–834.
9. Järvinen, H.J., Renkonen-Sinisalo, L., Aktán-Collán, K., Peltomäki, P., Aaltonen, L.A., Mecklin, J.P., Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. 10.1200/JCO.2009.23.7784 J Clin Oncol 27 (2009), 4793–4797.
10. Cross, D.S., Rahm, A.K., Kauffman, T.L., Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer. 10.1038/gim.2013.43 Genet Med 15 (2013), 933–940.
11. Colorectal cancer family history and genetic testing. http://www.michigan.gov/documents/mdch/MIBRFSS_Surveillance:Brief_Jul_2012_Vol6No3_FINAL_393196_7.pdf. Accessed 20 July 2013.
12. Pérez-Carbonell, L., Ruiz-Ponte, C., Guarinos, C., Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. 10.1136/gutjnl-2011-300041 Gut 61 (2012), 865–872.
13. Morrison, J., Bronner, M., Leach, B.H., Downs-Kelly, E., Goldblum, J.R., Liu, X., Lynch syndrome screening in newly diagnosed colorectal cancer in general pathology practice: from the revised Bethesda guidelines to a universal approach. 10.3109/00365521.2011.610003 Scand J Gastroenterol 46 (2011), 1340–1348.
14. EPICOLON Consortium, Identification of Lynch syndrome among patients with colorectal cancer. 1:CAS:528:DC%2BC38XhsFCrt7nI 10.1001/jama.2012.13088 JAMA 308 (2012), 1555–1565.
15. LIMO Study Group, Yield of routine molecular analyses in colorectal cancer patients =70 years to detect underlying Lynch syndrome. 1:CAS:528:DC%2BC38XjsVWhtr0%3D 10.1002/path.3963 J Pathol 226 (2012), 764–774.
16. Gudgeon, J.M., Belnap, T.W., Williams, J.L., Williams, M.S., Impact of age cutoffs on a lynch syndrome screening program. 10.1200/JOP.2012.000573 J Oncol Pract 9 (2013), 175–179.
17. Beamer, L.C., Grant, M.L., Espenschied, C.R., Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. 10.1200/JCO.2011.38.4719 J Clin Oncol 30 (2012), 1058–1063.
18. Cohen, S.A., Current Lynch syndrome tumor screening practices: a survey of genetic counselors. 10.1007/s10897-013-9603-5 J Genet Counsel 23 (2014), 38–47.
19. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. 10.1097/GIM.0b013e31818fa2ff Genet Med 11 (2009), 35–41.
20. Palomaki, G.E., McClain, M.R., Melillo, S., Hampel, H.L., Thibodeau, S.N., EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. 10.1097/GIM.0b013e31818fa2db Genet Med 11 (2009), 42–65.
21. Khoury, M.J., Bowen, M.S., Burke, W., Current priorities for public health practice in addressing the role of human genomics in improving population health. 10.1016/j.amepre.2010.12.009 Am J Prev Med 40 (2011), 486–493.
22. Ladabaum, U., Wang, G., Terdiman, J., Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. 10.7326/0003-4819-155-2-201107190-00002 Ann Intern Med 155 (2011), 69–79.
23. Mvundura, M., Grosse, S.D., Hampel, H., Palomaki, G.E., The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. 10.1097/GIM.0b013e3181cd666c Genet Med 12 (2010), 93–104.
24. Gudgeon, J.M., Williams, J.L., Burt, R.W., Samowitz, W.S., Snow, G.L., Williams, M.S., Lynch syndrome screening implementation: business analysis by a healthcare system. 21851136 Am J Manag Care 17 (2011), e288–e300.
25. Gausachs, M., Mur, P., Corral, J., MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. 1:CAS:528:DC%2BC38Xos1yjt7s%3D 10.1038/ejhg.2011.277 Eur J Hum Genet 20 (2012), 762–768.
26. DCCPS. Cancer control research: implementation science: RE-AIM. http://www.re-aim.org/. Accessed 20 July 2013.
27. Glasgow, R.E., Klesges, L.M., Dzewaltowski, D.A., Estabrooks, P.A., Vogt, T.M., Evaluating the impact of health promotion programs: using the RE-AIM framework to form summary measures for decision making involving complex issues. 10.1093/her/cyl081 Health Educ Res 21 (2006), 688–694.
28. Glasgow, R.E., Vogt, T.M., Boles, S.M., Evaluating the public health impact of health promotion interventions: the RE-AIM framework. 1:STN:280:DyaK1MvgtlOqtw%3D%3D 10.2105/AJPH.89.9.1322 Am J Public Health 89 (1999), 1322–1327.
29. Damschroder, L.J., Aron, D.C., Keith, R.E., Kirsh, S.R., Alexander, J.A., Lowery, J.C., Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. 10.1186/1748-5908-4-50 Implement Sci, 4, 2009, 50.
30. Ragin, C.C., The Comparative Method: Moving Beyond Qualitative and Quantitative Strategies. 1989, University of California Press.
31. Rihoux, B., Ragin, C.C., Configurational Comparative Methods: Qualitative Comparative Analysis (QCA) and Related Techniques. 10.4135/9781452226569, 2009, Sage.
32. Ragin C, Drass KA, Davey S. Fuzzy-Set/Qualitative Comparative Analysis 2.0. 2006. http://www.fsqca.com. Accessed 12 January 2012.
33. Hampel, H., Lattimer, I., Frankel, W.L., Universal Lynch syndrome screening result notification [abstract]. J Genet Counsel 21 (2012), 888–889.
34. Heald, B., Plesec, T., Liu, X., Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. 10.1200/JCO.2012.45.1674 J Clin Oncol 31 (2013), 1336–1340.
35. Lynch, P.M., How helpful is age at colorectal cancer onset in finding HNPCC?. 10.1007/DCR.0b013e31820e2f83 Dis Colon Rectum 54 (2011), 515–517.
36. South, C.D., Yearsley, M., Martin, E., Arnold, M., Frankel, W., Hampel, H., Immunohistochemistry staining for the mismatch repair proteins in the clinical care of patients with colorectal cancer. 1:CAS:528:DC%2BD1MXhsVSksbnN 10.1097/GIM.0b013e3181b99b75 Genet Med 11 (2009), 812–817.
37. Baxter, S., Jack, S., Qualitative case study methodology: study design and implementation for novice researchers. The Qualitative Report 13 (2008), 544–559.
38. Yin, R.K., Case Study Research: Design and Methods. 2008, Sage Publications.
39. Bellcross, C.A., Bedrosian, S.R., Daniels, E., Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. 10.1038/gim.0b013e31823375ea Genet Med 14 (2012), 152–162.